Prostate Surgery — Cost, Top Hospitals & Success Rates | MyMedicPlus

Prostate surgery is one of the most frequently performed urological procedures worldwide, addressing two distinct conditions — prostate cancer and benign prostatic hyperplasia (BPH) — with very different surgical approaches. For prostate cancer, radical prostatectomy (RP) removes the entire prostate gland along with the seminal vesicles and, when indicated, regional pelvic lymph nodes. The open retropubic radical prostatectomy, perfected by Patrick Walsh in the 1980s with nerve-sparing modifications, has been largely supplanted by minimally invasive techniques. Laparoscopic radical prostatectomy is now uncommon. Robot-assisted radical prostatectomy (RARP), using the da Vinci Surgical System or emerging platforms (Hugo RAS, Versius), now accounts for over 80% of radical prostatectomies in the United States and Europe. The da Vinci console provides 3D magnified stereoscopic visualization, wristed instrumentation with 7 degrees of freedom exceeding human hand range of motion, and real-time tremor filtration. For BPH (benign glandular enlargement causing bladder outlet obstruction), the range of surgical options reflects varying prostate sizes and patient priorities. Transurethral resection of the prostate (TURP) — the gold standard for prostates 30–80 mL — removes obstructing prostate tissue via electrocautery through the urethra. Holmium laser enucleation of the prostate (HoLEP) enucleates the entire adenoma and is the most effective endoscopic treatment regardless of prostate size. Newer office-based alternatives — Rezum (steam ablation), UroLift (prostatic urethral lift), and Aquablation (robotic water jet ablation) — offer sexual function preservation with lower morbidity but reduced durability compared to TURP or HoLEP.

Radical prostatectomy is indicated for clinically localized or locally advanced prostate cancer in patients with an estimated life expectancy of at least 10 years. Gleason grade groups 1–5 (corresponding to Gleason scores 6–10) and PSA values inform risk stratification: low-risk (cT1–T2a, Gleason ≤6, PSA <10), intermediate-risk (cT2b–T2c, or Gleason 7, or PSA 10–20), and high-risk (cT3–T4, or Gleason 8–10, or PSA >20) categories guide the extent of nerve-sparing and lymph node dissection. RARP is also considered in select high-risk patients who prefer surgery over radiation, with extended pelvic lymph node dissection. BPH surgical indications include acute urinary retention refractory to alpha-blockade, recurrent urinary tract infections attributable to incomplete bladder emptying, bladder stones arising from stasis, renal impairment due to obstructive uropathy, and significant lower urinary tract symptoms (LUTS) causing quality-of-life impairment despite adequate medical therapy (alpha-blockers, 5-alpha-reductase inhibitors, or combination therapy). Large prostates over 80 mL are best treated with HoLEP or simple open prostatectomy (Millin procedure), as TURP in this size range has higher transfusion and re-operation rates. Office-based procedures (Rezum, UroLift) are appropriate for men with smaller prostates (30–80 mL) who prioritize preservation of sexual function — particularly ejaculatory function.

Radical prostatectomy candidacy requires biopsy-confirmed prostate cancer, an ECOG performance status of 0–1, and sufficient life expectancy to benefit from curative local treatment. PSA level, biopsy Gleason grade group, and clinical stage define the risk category guiding extent of surgery. Pre-operative multiparametric MRI prostate (mpMRI — T2-weighted, DWI, DCE sequences) is now standard for surgical planning, characterizing extracapsular extension, seminal vesicle invasion, and nerve bundle involvement to guide unilateral or bilateral nerve-sparing. Bone scan is indicated if PSA exceeds 10 ng/mL with high-grade disease or if N1 disease is suspected. Pelvic lymph node dissection is performed in intermediate- and high-risk cancer; an extended template dissection (obturator, external iliac, internal iliac, and presacral nodes) removes more nodes and has better staging accuracy than limited dissection. For BPH surgery, urodynamic studies are helpful in patients with impaired detrusor contractility where the benefit of surgical outlet reduction is uncertain. Urine culture must be negative before elective prostate surgery. Anticoagulation management (bridging or cessation protocols) is essential, particularly for TURP where monopolar current requires saline-free irrigation. Sperm banking should be offered to men of reproductive age before radical prostatectomy, as anejaculation is universal following surgery.

For prostate cancer, three main surgical approaches exist. Robot-assisted radical prostatectomy (RARP) using the da Vinci Xi or SP platform is performed through 5–6 port sites, providing 3D 10x-magnified stereoscopic vision, wristed instrumentation, and tremor elimination. A nerve-sparing technique (unilateral or bilateral, intrafascial or interfascial) is applied based on preoperative mpMRI and intraoperative findings. Extended pelvic lymph node dissection (ePLND) — including external iliac, obturator, internal iliac, and presacral packets — is performed for intermediate- and high-risk disease. Open retropubic radical prostatectomy (RRP) remains the benchmark reference approach, utilising direct surgical exposure via lower midline incision, with tactile feedback for experienced surgeons. For benign prostatic hyperplasia (BPH), TURP using monopolar or bipolar electrocautery remains the gold standard for prostates 30–80 mL. Bipolar TURP in saline eliminates TUR syndrome risk, allowing larger resections. HoLEP (holmium laser enucleation of the prostate) uses a 100W holmium laser to enucleate the entire prostate adenoma along the surgical capsule plane, followed by endoscopic morcellation. HoLEP has no upper size limit and is the preferred endoscopic treatment for prostates over 80 mL. Office-based minimally invasive procedures include Rezum (steam vapour ablation, 9-minute office procedure), UroLift (prostatic urethral lift implants that mechanically retract the obstructing lateral lobes), and Aquablation (robotic waterjet-guided resection using real-time TRUS mapping). Simple open prostatectomy (Millin's retropubic or Freyer's suprapubic approach) is reserved for prostates over 150 mL or when cystolithotomy is required simultaneously.

Robot-assisted radical prostatectomy (RARP) offers equivalent oncological outcomes to open surgery — comparable positive surgical margin rates (10–20% for pT2 disease) and biochemical recurrence-free survival — combined with substantially reduced perioperative morbidity. Blood transfusion rate is below 5% with RARP versus 30–40% with open retropubic prostatectomy. Hospital stay is 1–2 days versus 3–5 days, and catheterization time is reduced (median 7 days vs 14 days open). The 5-year biochemical recurrence-free survival by risk group: low-risk 85–90%, intermediate-risk 70–80%, high-risk 50–60%. Long-term cancer-specific survival for localized disease is excellent — approximately 98–99% at 15 years for low-risk disease. Nerve-sparing RARP in young patients with unilateral or bilateral nerve preservation achieves pad-free continence in 90–95% at 12 months. For BPH, HoLEP is superior to TURP across all objective urodynamic parameters: IPSS (International Prostate Symptom Score) improvement from approximately 18 to 4, maximum urinary flow rate increase from a median of 8 mL/s to over 22 mL/s, post-void residual reduction, and lower re-operation rate (2–3% vs 8–15% for TURP at 10 years). HoLEP has no size limitation and is the procedure of choice for prostates over 80 mL.

Radical prostatectomy carries two well-recognized functional risks that significantly affect quality of life. Erectile dysfunction (ED) occurs in 40–70% of patients at 12 months, improving over time with nerve-sparing technique, younger age, and active penile rehabilitation using PDE5 inhibitors (sildenafil, tadalafil) commenced early in the post-operative period. Bilateral nerve-sparing in potent men under 60 achieves erectile function recovery in 50–80% at 18–24 months. Stress urinary incontinence — leakage during physical exertion — occurs in 3–20% of patients at 12 months depending on surgical technique and patient age, with most achieving social continence (no pad use) within 6–12 months through pelvic floor physiotherapy. Anastomotic stricture (bladder neck contracture at the vesicourethral anastomosis) occurs in 5–8% and is managed with endoscopic incision. Rectal injury is rare (less than 1%) but serious; lymphocele occurs in 2–5% after extended lymph node dissection. For TURP, TUR syndrome (dilutional hyponatremia from glycine absorption during monopolar TURP) is now rare with bipolar saline TURP but remains a historical concern. Retrograde ejaculation is nearly universal after TURP (80–90%), a significant concern for men who wish to preserve fertility. Urethral stricture develops in 5–10% after TURP, typically at the urethral meatus or bulbar urethra. HoLEP carries temporary stress urinary incontinence in 10–20% of patients in the immediate post-operative period (resolving in most within 3–6 months) and a learning curve of 30–50 procedures.

After radical prostatectomy for cancer, PSA measurement is the primary surveillance tool. PSA should be undetectable (below 0.1 ng/mL, ideally below 0.05 ng/mL) at 6–8 weeks post-operatively. Biochemical recurrence is defined as two consecutive PSA measurements above 0.2 ng/mL. PSA is measured every 3–6 months for the first 2 years, every 6 months to 5 years, then annually thereafter. Post-operative urinary continence assessment guides pelvic floor physiotherapy intensity; most patients achieve social continence within 6–12 months. Erectile function recovery is monitored and penile rehabilitation with daily PDE5 inhibitor therapy (sildenafil 25 mg or tadalafil 5 mg daily) or vacuum erection device use is initiated promptly. Bone-protective agents and metabolic monitoring are prescribed for patients receiving adjuvant androgen deprivation therapy. After BPH surgery (TURP/HoLEP), International Prostate Symptom Score (IPSS), urinary flow rate (Qmax), and post-void residual volume are assessed at 4–6 weeks and 3 months. Uroflowmetry confirms objective improvement. PSA monitoring continues annually to detect de novo prostate cancer.

Prostate surgery costs vary significantly by procedure type and country, making medical tourism particularly attractive for RARP, which requires specialized equipment. Robot-assisted radical prostatectomy (RARP): India $6,000–15,000 (da Vinci access at tertiary cancer centers); Thailand $12,000–25,000; Turkey $8,000–18,000; Mexico $10,000–20,000; USA $25,000–60,000; UK £15,000–35,000 (private); Australia AUD $25,000–50,000. Open radical prostatectomy: India $4,000–10,000; USA $15,000–35,000. TURP: India $2,000–5,000; USA $10,000–20,000; UK £4,000–8,000 (private, NHS covered as standard). HoLEP: India $3,000–8,000; USA $12,000–25,000; UK £6,000–14,000; Thailand $5,000–12,000. Office-based procedures: Rezum: USA $3,000–8,000; India $3,000–6,000 (limited availability). UroLift: USA $5,000–12,000; India $4,000–8,000. Aquablation: USA $12,000–22,000; India $6,000–12,000. Post-operative PSA surveillance every 3–6 months adds ongoing monitoring costs. Phosphodiesterase inhibitor therapy for erectile rehabilitation adds $50–200 per month in India and $100–400 per month in the USA.

For localised prostate cancer, active surveillance is a validated alternative for low-risk and selected favourable intermediate-risk disease, avoiding or deferring treatment while monitoring with PSA kinetics, MRI, and repeat biopsies. Radiation therapy — external beam radiotherapy (EBRT) using intensity-modulated radiotherapy (IMRT) with image guidance, or brachytherapy (permanent LDR seed implants or temporary HDR brachytherapy) — achieves equivalent long-term cancer control to surgery for localised disease with different risk profiles for erectile and urinary dysfunction. Focal therapy approaches — including HIFU (high-intensity focused ultrasound), cryotherapy, vascular-targeted photodynamic therapy (VTP), and focal laser ablation — target only the index tumor, preserving surrounding prostate tissue and reducing side effects, with medium-term cancer control data emerging. For BPH, medical therapy (alpha-blockers: tamsulosin, alfuzosin, silodosin; 5-alpha-reductase inhibitors: finasteride, dutasteride; or combination) effectively manages moderate LUTS in many patients without surgery. Prostate artery embolisation (PAE), a radiological intervention, reduces prostate volume by 15–30% via selective arterial embolisation without general anaesthesia, offering a surgical alternative for men with high surgical risk or ejaculatory function preservation priority.